ハーブ臨床用量 · 300–450mg/day (standardised to 55% bacosides)効果発現時間 · 8–12 weeks of consistent use (most positive trials ran 12 weeks)

Bacopa Monnieri

Name: Bacopa Monnieri — Human Clinical Effect Matrix
Creator: The Nootropic Lab
License: https://creativecommons.org/licenses/by/4.0/

A meta-analysis of 9 RCTs (Kongkeaw et al., 2014, n=518) found Bacopa shortened Trail Making B and choice reaction times versus placebo, and two 12-week RCTs in healthy older adults (Calabrese 2008; Morgan & Stevens 2010) improved delayed word recall at 300mg/day. The newest 12-week RCT (Lopresti 2025, n=101, 300mg/day) found no effect on verbal learning, attention or working memory, though it did reduce self-reported stress. A 2026 network meta-analysis of 29 RCTs found ≥600mg/day beat 300–450mg/day for working memory. Best evidence is for delayed recall rather than acute effects.

By The Nootropic Lab editorial teamUpdated 2026年10月9日8 min read✓ Fact-checked

エビデンス確認日: 2026年9月28日

作用機序

Bacopa enhances synaptic communication by increasing dendritic branching and synaptic density. Its active compounds (bacosides A and B) facilitate repair of damaged neurons and upregulate antioxidant activity, reducing oxidative stress in hippocampal tissue. It also modulates serotonin and acetylcholine systems.

臨床エビデンスの概要

ヒト効果マトリクス

Based on human clinical trials only. Animal and in-vitro data excluded.

効果	エビデンス	効果の大きさ	研究数	備考
Memory Consolidation	strong	中	4	Kongkeaw 2014 meta-analysis (9 RCTs), two 12-week RCTs on delayed recall, and a 2026 network meta-analysis (working memory, ≥600mg/day). The 2025 Lopresti RCT at 300mg/day did not replicate the memory benefit.
Anxiety Reduction	moderate	中	2	Calabrese 2008: anxiety fell with Bacopa and rose with placebo over 12 weeks; Lopresti 2025: lower self-reported stress reactivity.
Attention	mixed	小	2	Positive pooled speed-of-attention result (Kongkeaw 2014) but no effect on attention in the largest recent RCT (Lopresti 2025, p=0.713).
Processing Speed	mixed	小	2	An acute 320mg dose improved sustained task performance (2012), but the 2026 network meta-analysis found no processing-speed difference. Some users report temporary initial slowing.

Evidence key: Strong = multiple consistent RCTs · Moderate = smaller/fewer RCTs · Preliminary = early trials or small n · Mixed = conflicting results

実証された効果

Delayed recall in healthy older adults (12-week RCTs)
Anxiety and stress reduction
Antioxidant activity (laboratory studies)

副作用と注意事項

GI effects (increased stool frequency, abdominal cramps, nausea) reported at 300mg/day in a 12-week RCT in older adults — take with food
More self-reported adverse reactions than placebo (digestive complaints, headaches) in a 2025 12-week RCT
Slowed information processing initially
Not recommended during pregnancy (precautionary: no human safety data)

摂取方法

Dosage300–450mg/day (standardised to 55% bacosides) — the classic trial dose; ≥600mg/day is an emerging, less-established option

TimingWith your largest meal of the day — morning or evening both work

With foodBacosides are fat-soluble, so a meal with some fat is the standard advice. Taking it with food also helps with the GI side effects reported in trials. Do not take on an empty stomach.

FormsCapsule is most practical. Powder has a bitter, unpleasant taste. Look for standardisation to at least 40–55% bacosides on the label — unstandardised herbal products may contain very little active compound.

スタッキングの推奨

Bacopa Monnieriと相性の良い成分とその理由。

Lion's Mane

The definitive long-term memory stack. Bacopa improves synaptic density and memory consolidation; Lion's Mane drives NGF synthesis and neuroprotection. Both are slow-acting and complement each other without overlap.

Citicoline

Citicoline provides the acute focus and acetylcholine boost that Bacopa lacks in the short term, while Bacopa handles long-term memory consolidation. A well-rounded pairing found in Mind Lab Pro.

L-Theanine

Both have anxiolytic properties. L-Theanine provides immediate calm focus; Bacopa builds long-term stress resilience. The combination is gentle and well-tolerated.

よくある質問

Why do some people feel "foggy" when starting Bacopa?

A minority of users experience a temporary initial slowing of mental processing — sometimes called the "Bacopa fog." This is linked to the serotonin modulation and typically resolves after 3–4 weeks. It reflects the herb's mechanism working, not a problem. If it persists past 6 weeks, reduce your dose.

Do I really need to take it with fat?

It is the sensible default. Bacosides are fat-soluble compounds, and GI side effects (cramps, nausea, more frequent stools) were reported in trials, so taking Bacopa with a normal meal that contains some fat is the usual advice.

What percentage of bacosides should I look for?

Aim for 40–55% bacosides standardisation. The two most-studied commercial extracts (Bacognize and Synapsa) are both standardised. Generic "Bacopa" with no standardisation stated is unreliable — the active compound content may be negligible.

How long does it take to work?

The positive memory trials measured outcomes after 12 weeks. This is not a supplement you evaluate in the first month. Set a calendar reminder to assess at around 12 weeks — and note that the newest 12-week trial at 300mg/day found no cognitive benefit, so results vary.

Can Bacopa be taken long-term?

Most trials ran 12 weeks or less, so controlled data beyond that is thin. Traditional Ayurvedic use is continuous without cycling, and no trial has shown cycling is necessary — but long-term safety has not been studied directly.

Top stacks containing Bacopa Monnieri

Mind Lab Pro

9.4/10

Opti-Nutra

Editor's Choice

NooCube

7.6/10

Wolfson Brands

Hunter Focus

7.7/10

Roar Ambition

Bacopa Monnieri in Japan

Bacopa monnieri is entered in MHLW's food-drug list under the Japanese name オトメアゼア (the CAA report writes it オトメアゼナ; alternate name バコパモニエラ), part 全草 (whole plant), on 別添２ — the half of the list covering ingredients not automatically treated as pharmaceuticals absent a drug-like claim. A Consumer Affairs Agency Foods with Function Claims verification report cites this directly, noting "バコパ（オトメアゼナ）は非医。", and records a real notification, D235 「記憶の小箱」 by Nihon Shinyaku Co., built on バコパサポニン (bacopa saponin) as the functional ingredient, with claim text: "本品にはバコパサポニンが含まれます。バコパサポニンには、認知機能の一部である記憶力（加齢により低下する日常生活で見聞きした情報を覚え、思い出す力）を維持する機能があることが報告されています。" That report also records the product as suspended from sale as of its 2019 reference date.

Bacopa's MHLW classification and a CAA-notified product

MHLW's food-drug list carries bacopa monnieri under the Japanese name オトメアゼア (spelled オトメアゼナ in the CAA report), with バコパモニエラ recorded as the alternate name and 全草 (whole plant) as the part covered, placed on 別添２, the non-exclusively-pharmaceutical half of the list. The Consumer Affairs Agency's own FY2019 verification report cross-references this MHLW determination directly ("バコパ（オトメアゼナ）は非医。") while reviewing notification D235, 「記憶の小箱」, a Nihon Shinyaku Co. product notified with bacopa saponin （バコパサポニン） as its functional ingredient and a memory-maintenance claim. The same report entry notes the product's sales status as suspended as of the report's 2019/5/27 reference date, which does not necessarily reflect current availability.

Products in Japan

Consumer Affairs Agency (FFC)

Is bacopa monnieri treated as a food ingredient in Japan?

Yes — MHLW's list places bacopa monnieri (オトメアゼア, alternate name バコパモニエラ, whole plant) on 別添２, the half of its food-drug classification list for ingredients not automatically judged pharmaceutical absent a drug-like claim, and a CAA verification report explicitly notes "バコパ（オトメアゼナ）は非医。"

Has bacopa monnieri carried a notified functional claim in Japan?

Yes, per the CAA's FY2019 report: notification D235, 「記憶の小箱」 by Nihon Shinyaku Co., used bacopa saponin （バコパサポニン） as the functional ingredient with a memory-maintenance claim, though that report recorded the product as suspended from sale as of its 2019 reference date.

Prefecture guides

Sources: CAA — H31年度機能性表示食品検証報告書, MHLW non-pharmaceutical cross-reference for bacopa · CAA — H31年度機能性表示食品検証報告書, notification D235 claim text · MHLW — 食薬区分における成分本質（原材料）の取扱いの例示の一部改正について (令和5年2月17日薬生監麻発第217001号), 別添２ entry · MHLW — 別添2 heading: 医薬品的効能効果を標ぼうしない限り医薬品と判断しない成分本質（原材料）リスト, 1. 植物由来物等

Regulatory note

本ページは教育目的の編集コンテンツであり、医学的助言を構成するものではありません。日本国内で販売される機能性表示食品（FFC）および特定保健用食品（FOSHU）は、消費者庁への届出または許可を必要とします。届出のない輸入品については、日本の薬機法（旧薬事法）の下で疾病治療を示唆する表現は規制されます。サプリメントを開始する前に、必ず資格のある医療専門家にご相談ください。This page is editorial and not medical advice. Foods with Function Claims (FFC) and Foods for Specified Health Uses (FOSHU) sold in Japan require notification or approval from the Consumer Affairs Agency. Imported products without notification cannot make disease-treatment claims under the Pharmaceuticals and Medical Devices (PMD) Act. Note: In July 2026, the Consumer Affairs Agency (CAA) opened a public comment period (Notice No. 235080088, closes 30 July 2026) on proposed revisions to permitted claim wording for FFC-notified ingredients including DHA, phosphatidylserine, and NMN; compliant claim language may require updating once the final Cabinet Office Order is published. Consult a qualified healthcare professional before starting any supplement.

出典 (6)展開

← 成分ガイドに戻る